Fall 2007 - Biomet 3i

L I T E R A T U R E R E V I E W C O N T I N U E DImmediate Provisionalization On A New Implant DesignFor Esthetic Restoration And Preserving Crestal BoneJosé Luis Calvo Guirado, DDS, PhDMaria Rosario Saez Yuguero, DDS, PhDGuillermo Pardo Zamora, DDS, PhDEmilio Muñoz Barrio, DDS, PhDImplant Dentistry 16(2):155-64 June 2007PurposeThis article describes how the concept of platform switching has beenincorporated into a new implant design as a method of reducing crestalbone loss and maintaining the gingival papillae. A 6-month study of theeffects of this implant on bone loss is described.MaterialsTen new platform switched implants were placed into fresh anteriormaxillary extraction sites in 3 men and 7 women, ranging in agebetween 29 and 45 years old, and immediately provisionalized. Theadjoining bone height was evaluated with digital radiography on the dayafter implant placement, and at 15 days, 1, 2, 3, and 6-months later.ResultsAfter 6-months, the mean bone loss on the mesial of thecentral-incisor implants was 0.05mm. The mean bone loss was0.07mm on the distal of the central incisor implants, 0.07mmon the mesial of the lateral-incisor implants, and 0.06mm onthe distal of the lateral-incisor implants.ConclusionAn implant design that incorporates the concept of platform switching is asimple and effective way to control circumferential bone loss around dentalimplants, helping to ensure a predictable esthetic result.When Clinicians Think “Nanotechnology”, BIOMET 3i Comes To MindThe Millennium Research Group (MRG) has conducted a detailed analysisof the U.S. dental implant market in its U.S. Markets for Dental Implants2007 report. The analysis reveals that nanotechnology is creating a newbuzz in the dental implant market.These results indicate that most respondents identified [BIOMET] 3i as thenanotechnology-based dental implant surface manufacturer with whichthey were most familiar.For further information, please contact Amy Krohn, Millennium ResearchGroup, 416-364-7776 x101 or akrohn@mrg.net.Millennium Research Group (http://www.mrg.net/), a Decision Resources,Inc. company (http://www.decisionresources.com/), is the global authorityon medical technology market intelligence and a leading provider ofstrategic information to the health care sector. Focused solely on themedical device, pharmaceutical and biotechnology industries, the companyprovides its clients with the benefits of its specialized industry expertisethrough published reports and customized consulting services.All company, brand, or product names contained in this document maybe trademarks or registered trademarks of their respective holders.S I G N U P A N D S T A Y C O N N E C T E DIn The OperatoryNew on the BIOMET 3i Website isIn The Operatory, where clinicians canview a case in book format. To view, visitour Home Page at www.biomet3i.comand click on the In The Operatory box.A Clinical PerspectiveTo receive some of the latest clinicalinformation from BIOMET 3i, sign upfor our bimonthly electronic newsletterBIOMET 3innovations. Simply go onlineto www.biomet3i.com/signup.9